AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior versions of the claims presented in the application.

Claim 1 (Currently amended): A compound represented by formula (1):

$$\begin{array}{c}
A \\
N - CO - B - Z
\end{array}$$
(1)

(wherein wherein,

R1 represents a hydrogen atom or a C₁₋₆ alkyl group which may be substituted,

A represents an imidazolyl group or a pyrazolyl group represented by the following formulae:

(wherein wherein,

R2 and R3 represent a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1,

R4 represents a hydrogen atom or a C_{1-6} alkyl group which may be substituted by G1, a C_{1-6} alkylcarbonyl group which may be substituted by G1, or a benzoyl group which may be substituted by G1,

n represents 0 or an integer of 1 to 3,

p represents 0 or an integer of 1 or 2, and

R2 and R3 may be identical to each other, or different from each other, when n and p are 2 or more[[)]],

B represents a group represented by the following formula:

Application No. 10/553,108 Docket No.: 20241/0203481-US0

Amendment dated September 24, 2008 After Final Office Action of June 27, 2008

(wherein wherein,

R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{2-6} alkenyl group, a C_{2-6} alkenyloxy group, a C_{2-6} alkynloxy group, a C_{1-6} acyloxy group, or a C_{3-6} cycloalkyl group, or a phenyl group which may have a substituent,

k represents 0 or an integer of 1 to 15, and

R5 and R6 may be identical to each other, or different from each other, when k is 2 or more[[)]], and

Z represents a chroman-2-yl group which is substituted by G2, a 2,3-dihydrobenzofuran-2-yl group which is substituted by G2, a 2,3-dihydrobenzothiophene-2-yl group which is substituted by G2, a 2,3-dihydrobenzothiophene-2-yl group which is substituted by G2, or a 1,3-benzoxathiol-2-yl group which is substituted by G2,

G1 represents a cyano group, a formyl group, a hydroxyl group, an amino group, a dimethylamino group, or a halogen atom,

G2 is represented by the following formula: NHR (wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent[[)]], or a pharmaceutically acceptable salt thereof.

Application No. 10/553,108 Docket No.: 20241/0203481-US0

Amendment dated September 24, 2008 After Final Office Action of June 27, 2008

Claim 2 (original): A compound or pharmaceutically acceptable salt according to claim 1, wherein z is a group represented by the following formula (A), (B) or (C):

$$R7$$
 $R7$
 $G2$
 $R10$
 $R8$
 $R14$
 $R13$
 $R15$
 $R15$
 $R15$
 $R16$
 $R17$
 $R17$
 $R17$
 $R17$
 $R17$
 $R18$
 $R19$
 $R19$

(wherein

* represents an asymmetric carbon atom,

X1 represents an oxygen atom or a sulfur atom,

R7 to R17 each independently represents a hydrogen atom or a C₁₋₆ alkyl group, and

G2 is represented by the following formula: NHR

(wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent)).

Claim 3 (previously presented): A compound or pharmaceutically acceptable salt according to claim 1, wherein A is 1-imidazolyl or 1-H-pyrazole-5-yl which is substituted at the fourth position on the benzene ring.

Claim 4 (withdrawn): A production process of a compound represented by formula (1):

$$\begin{array}{c}
A \\
N - CO - B - Z
\end{array}$$
(1)

(wherein,

R1 represents a hydrogen atom or a C₁₋₆ alkyl group which may be substituted,

A represents an imidazolyl group or a pyrazolyl group represented by the following formulae:

(wherein

R2 and R3 represent a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1,

R4 represents a hydrogen atom or a C_{1-6} alkyl group which may be substituted by G1, a C_{1-6} alkylcarbonyl group which may be substituted by G1, or a benzoyl group which may be substituted by G1,

n represents 0 or an integer of 1 to 3,

p represents 0 or an integer of 1 or 2, and

Application No. 10/553,108 Amendment dated September 24, 2008 After Final Office Action of June 27, 2008

R2 and R3 may be identical to each other, or different from each other, when n and p are 2 or more),

B represents a group represented by the following formula:

(wherein

R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{2-6} alkenyl group, a C_{2-6} alkenyloxy group, a C_{2-6} alkenyloxy group, a C_{2-6} alkynloxy group, a C_{1-6} acyloxy group, or a C_{3-6} cycloalkyl group, or a phenyl group which may have a substituent,

k represents 0 or an integer of 1 to 15, and

R5 and R6 may be identical to each other, or different from each other, when k is 2 or more),

Z represents a chroman-2-yl group which is substituted by G2, a 2,3-dihydrobenzofuran-2-yl group which is substituted by G2, a 2,3-dihydrobenzothiophene-2-yl group which is substituted by G2, a 2,3-dihydrobenzothiophene-2-yl group which is substituted by G2, or a 1,3-benzoxathiol-2-yl group which is substituted by G2,

G1 represents a cyano group, a formyl group, a hydroxyl group, an amino group, a dimethylamino group, or a halogen atom, and

G2 is represented by the following formula: NHR (wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent), comprising:

a step 1 in which a compound represented by the following formula (1')

(wherein

R1 represents a hydrogen atom or a C_{1-6} alkyl group which may be substituted,

A represents an imidazolyl group or a pyrazolyl group represented by the following formulae:

(wherein

R2 and R3 represent a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1,

R4 represents a hydrogen atom or a C_{1-6} alkyl group which may be substituted by G1, a C_{1-6} alkylcarbonyl group which may be substituted by G1, or a benzoyl group which may be substituted by G1,

n represents 0 or an integer of 1 to 3,

p represents 0 or an integer of 1 or 2, and

R2 and R3 may be identical to each other, or different from each other, when n and p are 2 or more)),

B represents a group represented by the following formula:

(wherein

R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{2-6} alkenyl group, a C_{2-6} alkenyloxy group, a C_{2-6} alkenyloxy group, a C_{2-6} alkynloxy group, a C_{1-6} acyloxy group, or a C_{3-6} cycloalkyl group, or a phenyl group which may have a substituent,

k represents 0 or an integer of 1 to 15, and

R5 and R6 may be identical to each other, or different from each other, when k is 2 or more), and

Z' is represented by the following formula (A)', (B)', or (C)':

(wherein

* represents an asymmetric carbon atom,

X1 represents an oxygen atom or a sulfur atom,

R7 to R17 each independently represents a hydrogen atom or a C₁₋₆ alkyl group, and

G2 is represented by the following formula: NHR

(wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent))

is produced by reacting an amine compound represented by formula (2):


$$\stackrel{\mathsf{A}}{\underset{\mathsf{R}}{\bigvee}} \stackrel{\mathsf{H}}{\underset{\mathsf{R}}{\bigvee}} \qquad \qquad (2)$$


(wherein

R1 represents a hydrogen atom or a $C_{1\text{--}6}$ alkyl group which may be substituted, and

A represents an imidazolyl group or a pyrazolyl group represented by the following formulae:

Application No. 10/553,108 Amendment dated September 24, 2008 After Final Office Action of June 27, 2008 Docket No.: 20241/0203481-US0





(wherein

R2 and R3 represent a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1,

R4 represents a hydrogen atom or a C_{1-6} alkyl group which may be substituted by G1, a C_{1-6} alkylcarbonyl group which may be substituted by G1, or a benzoyl group which may be substituted by G1,

n represents 0 or an integer of 1 to 3,

p represents 0 or an integer of 1 or 2, and

R2 and R3 may be identical to each other, or different from each other, when n and p are 2 or more))

with a compound represented by the following formula (3):

$$YOC-B-Z'$$
 (3)

(wherein

Y represents a hydroxyl group or a halogen atom,

B represents a group represented by the following formula:

(wherein

R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{2-6} alkenyl group, a C_{2-6} alkenyloxy group, a C_{2-6} alkynloxy group, a C_{1-6} acyloxy group, or a C_{3-6} cycloalkyl group, or a phenyl group which may have a substituent,

k represents 0 or an integer of 1 to 15, and

R5 and R6 may be identical to each other, or different from each other, when k is 2 or more) and

Z' is represented by the following formula (A)', (B)', or (C)':

$$*$$
 $R10$
 X_1
 $R9$
 $R8$
 $R14$
 X_1
 $R13$
 $R15$
 $R15$
 $R10$
 $R17$
 $R16$
 $R17$
 $R17$
 $R17$
 $R17$
 $R18$
 $R19$
 $R1$

(wherein

* represents an asymmetric carbon atom,

X1 represents an oxygen atom or a sulfur atom,

R7 to R17 each independently represents a hydrogen atom or a C₁₋₆ alkyl group, and

G2 is represented by the following formula: NHR

(wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent)); and

a step 2 in which the nitro compound produced in the step 1 is converted to an amino group using a reducing agent.

Claim 5 (original): An antioxidant comprising as its active ingredient at least one compound represented by formula (1):

$$\begin{array}{c}
A \\
\hline
N-CO-B-Z \\
R1
\end{array}$$
(1)

(wherein

R1 represents a hydrogen atom or a C₁₋₆ alkyl group which may be substituted,

A represents an imidazolyl group or a pyrazolyl group represented by the following formulae:

(wherein

R2 and R3 represent a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1,

R4 represents a hydrogen atom or a C_{1-6} alkyl group which may be substituted by G1, a C_{1-6} alkylcarbonyl group which may be substituted by G1, or a benzoyl group which may be substituted by G1,

n represents 0 or an integer of 1 to 3,

p represents 0 or an integer of 1 or 2, and

R2 and R3 may be identical to each other, or different from each other, when n and p are 2 or more)),

B represents a group represented by the following formula: (wherein

R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₂₋₆ alkenyloxy group, a C₂₋₆ alkynloxy group, a C₁₋₆ acyloxy group, or a C₃₋₆ cycloalkyl group, or a phenyl group which may have a substituent,

k represents 0 or an integer of 1 to 15, and

R5 and R6 may be identical to each other, or different from each other, when k is 2 or more),

Z represents a chroman-2-yl group which is substituted by G2, a 2,3-dihydrobenzofuran-2-yl group which is substituted by G2, a thiochroman-2-yl group which is substituted by G2, a 2,3-

dihydrobenzothiophene-2-yl group which is substituted by G2, or a 1,3-benzoxathiol-2-yl group which is substituted by G2,

G1 represents a cyano group, a formyl group, a hydroxyl group, an amino group, a dimethylamino group, or a halogen atom, and

G2 is represented by the following formula: NHR (wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent) or a pharmaceutically acceptable salt thereof.

Claim 6 (original): An antioxidant according to claim 5, wherein in formula (1) z is represented by the following formula (A), (B), or (C):

$$R7$$
 $R7$
 $R9$
 $R10$
 $R10$

X1 represents an oxygen atom or a sulfur atom,

R7 to R17 each independently represents a hydrogen atom or a C_{1-6} alkyl group, and G2 is represented by the following formula: NHR

^{*} represents an asymmetric carbon atom,

Application No. 10/553,108

Amendment dated September 24, 2008

After Final Office Action of June 27, 2008

(wherein R represents a hydrogen atom, a C₁₋₆ alkylcarbonyl group, or a benzoyl group which may

have a substituent)).

Claim 7 (withdrawn): A kidney disease, cerebrovascular or cardiovascular disease treatment

agent characterized by comprising the antioxidant according to claim 6.

Claim 8 (withdrawn): A cerebral infarction treatment agent characterized by comprising the

antioxidant according to claim 6.

Claim 9 (withdrawn): A retinal oxidation disorder inhibitor characterized by comprising the

antioxidant according to claim 6.

Claim 10 (withdrawn): A retinal oxidation disorder inhibitor according to claim 9 for age-

related macular degeneration or diabetic retinopathy.

Claim 11 (withdrawn): A lipoxygenase inhibitor characterized by comprising the antioxidant

according to claim 6.

Claim 12 (withdrawn): A 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor

characterized by comprising the antioxidant according to claim 6.

15

3317195.1 0203481-US0

Amendment dated September 24, 2008

Claim 13 (previously presented): A compound or pharmaceutically acceptable salt according to claim 2, wherein A is 1-imidazolyl or 1-H-pyrazole-5-yl which is substituted at the fourth position on the benzene ring.

Claim 14 (previously presented): A compound or pharmaceutically acceptable salt according to claim 1, wherein R1 is a hydrogen atom, A is 4-(1H-pyrazole-5-yl), k is 0, and Z is represented by the following formula: